On the basis of these findings, a patient with recurrent, refractory thyroid cancer was recruited and received TSHR + CD19 CAR-T-cell therapy; this patient achieved partial remission within 3 months and tolerated the treatment well. Here, TSHR is linked to thyroid gland carcinoma.